Medical Dynamics

“Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes” (PharmaLive)

“Intelence (etravirine):Reports of severe, potentially life-threatening and fatal skin reactions” (MedWatch)

“Four studies published in The Lancet show roflumilast (Daxas®), a new oral approach to COPD, improves lung function and reduces exacerbations” (PharmaLive)

Read the rest of this entry »

“Index May Aid COPD Risk Assessment” (MedPage Today)

“CVS Caremark Data Finds More than 50 Percent of Adults 45-years and Younger are not Adherent to Cholesterol Lowering Medications” (PharmaLive.com)

“Studies show potential for Nycomed’s COPD drug Daxas” (PharmaTimes.com)

Read the rest of this entry »

“Updates for Antares Pharma, Teva, AVI, NeoStem” (American Chronicle)

“New Technology Helps Parkinson’s Patients Speak Louder” (Science)

“Twitter and Health Care: Can A Tweet A Day Keep The Doctor Away?” (Science)

Read the rest of this entry »

“Biovail, Santhera strike Parkinson’s drug deal” (Reuters Health)

“Uproar as NICE turns down appeal over kidney cancer drugs” (PharmaTimes.com)

“Europe ‘ahead of US in drug discover’” (PharmaTimes.com)

Read the rest of this entry »

“Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler; Artefill Proven to Deliver Patients a Solution for Younger, Natural and Smoother Looking Skin” (PR Newswire) –

“Testosterone Supplementation Benefits Men With Heart Failure” (Elsevier Global Medical News)

This is copyright protected information, to receive the full article, please click here to sign up and register.

“Santhera Licenses North American Rights For Parkinson’s Drug To Biovail” (The Pink Sheet Daily)

This is copyright protected information, to receive the full article, please click here to sign up and registe.

Read the rest of this entry »

“Computer System Improves Pain Therapy for Cancer Patients” (Science)

“Off-label Use Often Not Evidence-Based: Physicians Lack Knowledge of Off-label Drug Use and FDA Approval Status, Study Finds” (Science)

“Diacetylmorephine Compares Favorably with Methadone” (Elsevier Global Medical News)

Treatment with injectable diacetylmorphine, the active ingredient in heroin, compared favorably with methadone treatment in a phase III clinical trial reported in the Aug. 20 issue of the New England Journal of Medicine.

This is copyright protected information, to receive the full article, please click here to sign up and register.

Read the rest of this entry »

“Consumer groups urge transparency in health care reform for pharmacy benefit managers” (The Medical News)

“EGFR Inhibitors Useful in Subset of Patients With NSCLC” (Elsevier Global Medical News)

Two inhibitors of the epidermal growth factor receptor tyrosine kinase–gefitinib and erlotinib–were effective for patients with non-small cell lung cancer who carried mutations of the EGFR gene, according to separate phase III clinical trials published online in the New England Journal of Medicine.

This is copyright protected information, to receive the full article, please click here to sign up and register.

“Eloxatin’s Wild Ride: Generics Back on the Market After Five-Day Stay of Approval” (The Pink Sheet)

Teva and Hospira relaunched their generic Eloxatin (oxaliplatin) on Aug. 19 after the D.C. Circuit Court of Appeals dissolved its stay of FDA approval of oxaliplatin ANDAs.

This is copyright protected information, to receive the full article, please click here to sign up and register.

Read the rest of this entry »

“Research and Markets: Allergan: Performance, Products, Pipeline and Potential” (Business Wire)

“FDA Proposes Mandatory Electronic Safety Reporting, New Rules will help Strengthen Postmarket Safety Data Collection” (FDA)

“Bristol-Myers Squibb Announces Preliminary Court Approval of Derivative Settlement” (PharmaLive.com)

Read the rest of this entry »

“U.S. researchers see few serious reactions to HPV vaccine” (Reuters)

“Low-dose estrogen may help if breast cancer recurs” (Reuters)

“Heart attack deaths fall after Medicare guidelines” (Reuters)

Read the rest of this entry »

“GSK strengthens its vaccines alliance with Brazil’s Fiocruz” (PharmaTimes.com)

“Aeterna shares plunge as cetrorelix Phase III trial misses endpoint” (PharmaTimes.com)

“Antioxidant Supplements Don’t Raise Melanoma Risk” (The Pink Sheet)

Antioxidant supplements do not appear to increase the risk of melanoma, according to a report in the August issue of the Archives of Dermatology.

This is copyright protected information, to receive the full article, please click here to sign up and register.

Read the rest of this entry »